The 5 April 2024 Announcement POSITIVE OUTCOMES IN BIT225 PHASE...

The 5 April 2024 Announcement

POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV (BIT225-010)

Stated That:

The double-blind placebo-controlled Phase 2 trial
was designed to characterise the effect of BIT225 (200 mg, once daily for 24 weeks)
added to a standard of care antiretroviral therapy cART:
50 mg Dolutegravir (DTG),
300 mg Tenofovir disproxil fumarate (TDF) and
200 mg Emtricitabine (FTC)


So the question may be who makes the cART drugs?

Dolutegravir (DTG), is owned by Viiv Healthcare (majority-owned by GSK, with Pfizer Inc)
Tenofovir disproxil fumarate (TDF) is owned by Gilead
Emtricitabine (FTC) is owned by Gilead

That perhaps may give some indication of who potential partners could be....